As shown in Figure 3F (blue bars), at high transgene dosage levels VP1::FUS3-B3 exhibited the greatest capacity for ABA-dependent activation of CRC, whereas activities of VP1::ABI3-B3 and VP1::LEC2-B3 were intermediate and higher than VP1::VAL1-B3. The gene discussed is ADGRL1; the disease is colorectal carcinoma.